Our initial class of drugs works through the carotid body to improve rate, rhythm and respiratory output.
|11-Apr-2013||Galleon Pharmaceuticals Demonstrates Successful Clinical Proof-of-Concept for Lead Product from Sleep Apnea Drug-Discovery Platform|
|20-Sep-2012||Galleon Pharmaceuticals Reports Positive Results from Second Phase I Study of GAL-021 for Treatment of Respiratory Depression|
|7-May-2012||Galleon Pharmaceuticals Reports Positive Results from Phase I Study of GAL-021 For Treatment of Respiratory Depression|
|1-Dec-2011||Galleon Pharmaceuticals Names Lynne Brookes Senior Vice President and Chief Business Officer|
|1-Nov-2011||Galleon Pharmaceuticals Names Two Executives to Senior Drug Discovery and Clinical Development Positions|
|26-Oct-2011||Thomas Dietz, Ph.D, Elected Chairman of Galleon Pharmaceuticals|
|1-May-2006||Galleon Pharmaceuticals is named SR ONE Biotech Company of the Year for Innovative Approach in Developing Sleep Apnea Medicines|